HLA and MHC refer to the same biological system, just at different levels of specificity. MHC, short for major histocompatibility complex, is the umbrella term used for any vertebrate species. HLA, short for human leukocyte antigen, is the name for the MHC system specifically in humans. The confusion between the two terms comes from a naming split that dates back to mid-twentieth-century immunology, and it persists because researchers studying mice, fish, or birds use “MHC” while clinicians managing transplants or autoimmune disease in people almost always say “HLA.” Understanding this relationship matters because the same set of genes controls everything from organ transplant rejection to drug allergies to how well your immune system fights off a virus.
Why Two Names Exist
The story starts with mice. In the 1930s and 1940s, researchers studying tumor transplants between inbred mouse strains discovered a cluster of genes on chromosome 17 that determined whether grafted tissue would be accepted or rejected. They called it the H-2 system. It was the discovery of H-2 that foreshadowed the later identification of an equivalent system in humans.1Oxford University Press. A historical perspective on HLA When human researchers found comparable genes on chromosome 6 in the 1950s and 1960s, they named them after the context in which they were first detected: antigens on the surface of white blood cells, or leukocytes. Hence “human leukocyte antigen.”
Meanwhile, as equivalent gene clusters turned up in chickens, rats, fish, and virtually every other vertebrate studied, the field needed a species-neutral label. “Major histocompatibility complex” filled that role. So MHC is the generic category, and each species gets its own shorthand: H-2 in mice, HLA in humans, BoLA in cattle, Mamu in macaques, and so on. When you read “MHC class I molecule” in a textbook, the statement applies across vertebrates. When you read “HLA-B*57:01” in a clinical report, the statement applies to one specific gene variant in one species: ours.
What These Molecules Actually Do
The core job of MHC molecules is to display fragments of proteins on the surface of your cells so that T cells of the immune system can inspect them. Think of it as a shop window: the MHC molecule holds up a short piece of a protein (a peptide) for passing T cells to examine. If the peptide looks like something that belongs to you, T cells move on. If it looks foreign, say a fragment of a virus, the T cell mounts an immune response.
This inspection system is central to how your body distinguishes “self” from “non-self.” T cells are selected in the thymus early in life so that only those capable of recognizing peptides presented by your own MHC molecules survive and mature.2PubMed Central. Revisiting thymic positive selection and the mature T cell repertoire for antigen This process, called MHC restriction, means your T cells are permanently tuned to your personal set of MHC molecules. It is also why transplanting tissue from someone with different HLA types triggers rejection: the recipient’s T cells see the donor’s MHC molecules as foreign and attack.
The Three Classes of MHC Genes
The HLA region on chromosome 6 spans roughly 3.4 megabases and is traditionally divided into three classes, each with distinct functions.
Class I genes (HLA-A, HLA-B, and HLA-C are the main ones) encode molecules found on the surface of nearly every nucleated cell in the body. Their job is to present peptides from proteins made inside the cell, including viral proteins if the cell is infected. Cytotoxic T cells (CD8+ T cells) are the inspectors here. When they spot a foreign peptide in a class I molecule, they kill the infected cell. This pathway relies on a loading complex inside the cell where a protein called tapasin helps slot peptides into class I molecules before they travel to the surface.3PubMed. Molecular architecture of the TAP-associated MHC class I peptide-loading complex Efficient recognition of infected or abnormal cells by these killer T cells depends on functional class I molecules presenting the right peptides.4PubMed. Hsp72-mediated augmentation of MHC class I surface expression and endogenous antigen presentation
Class II genes (HLA-DR, HLA-DQ, and HLA-DP) encode molecules with a more restricted distribution. They appear mainly on professional antigen-presenting cells like dendritic cells, macrophages, and B cells.5PubMed Central. The ins and outs of MHC class II-mediated antigen processing and presentation Instead of displaying peptides from inside the cell, class II molecules typically present fragments of proteins that the cell has swallowed from outside, such as parts of a bacterium. Helper T cells (CD4+ T cells) read these displays and coordinate broader immune responses, including helping B cells make antibodies. An alternative pathway has also been documented in which class II molecules can load peptides through the same internal machinery normally used by class I, though this appears to occur mainly in specialized situations like certain leukemic cells.6PubMed Central. Alternative Ii-independent antigen-processing pathway in leukemic blasts involves TAP-dependent peptide loading of HLA class II complexes
The class III region sits physically between the class I and class II regions on the chromosome but encodes a grab-bag of immune-related proteins that are not MHC molecules in the peptide-presenting sense. These include complement components, cytokines like tumor necrosis factor (TNF), and other inflammatory regulators.7PubMed. Human MHC class III and IV genes and disease associations A conserved block of five genes in this region, including TNF and lymphotoxin genes, has been linked to the severity and chronicity of arthritis in both animal models and human patients with rheumatoid arthritis.8PubMed Central. Conserved 33-kb haplotype in the MHC class III region regulates chronic arthritis
Why HLA Genes Are So Diverse
One of the most striking features of HLA genes is their extreme variability. Some HLA loci have thousands of known variants in the human population, making the HLA region the most polymorphic part of the entire human genome. This diversity is maintained by natural selection: populations benefit from carrying many different versions of these molecules because each version can display a different set of pathogen-derived peptides to T cells.9PubMed Central. Human leukocyte antigen gene polymorphism and the histocompatibility laboratory A population with a wide range of HLA types is harder for any single pathogen to evade completely.
This diversity also explains why finding a perfectly matched organ donor is so difficult. Because each person inherits one set of HLA genes from each parent, the number of possible combinations is astronomical. The odds of two unrelated people sharing all the clinically relevant HLA types are low, which is why transplant registries worldwide maintain databases of millions of potential donors.
MHC Across Species
Looking at MHC systems across species reveals that the basic architecture is ancient but not frozen. Humans, macaques, and mice all have class I, class II, and class III regions, but the sizes differ considerably. The human HLA region spans about 3.4 megabases from class I to class II; the equivalent region in the rhesus macaque (Mamu) stretches to about 4.7 megabases, while the mouse H-2 region is smaller at roughly 2.9 megabases.10PubMed Central. Comparative genomics of the human, macaque and mouse major histocompatibility complex Much of the size difference comes from duplications in the class I region: macaques have significantly expanded their class I gene repertoire compared to humans.
Farther afield, the organization changes more dramatically. In chickens and frogs, all three MHC classes remain linked on one chromosome.11PubMed. Comparative genomics of medaka: the major histocompatibility complex (MHC) But in bony fish (teleosts), the class I and class II genes are not linked at all, sitting on separate chromosomes entirely. This suggests that the tight clustering humans take for granted resulted from genomic reorganization during vertebrate evolution, and the linkage we see in mammals is not the only way to build a functional immune presentation system. Poultry MHC systems have attracted particular attention because certain chicken MHC haplotypes confer strong disease resistance, making them relevant to agricultural breeding programs.12Animal Science Journal. Comparative genomics of the poultry major histocompatibility complex
Transplantation and HLA Matching
The clinical arena where HLA terminology dominates most completely is transplantation. When a patient needs a bone marrow or stem cell transplant, the degree of HLA matching between donor and recipient is one of the strongest predictors of success. In unrelated donor transplants, mismatches at the HLA-A, -B, -C, or -DRB1 loci are each independently associated with higher mortality.13PubMed Central. Evaluation of HLA matching in unrelated hematopoietic stem cell transplantation for nonmalignant disorders A single mismatch at any of these loci roughly doubles the odds of graft failure compared to a fully matched donor, and a double mismatch pushes the risk even higher.
Mismatches at class I loci (HLA-A, -B, and -C) have been specifically linked to engraftment failure, meaning the transplanted cells fail to take hold in the recipient’s bone marrow.14PubMed. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors Beyond HLA typing, clinicians now also test for donor-specific anti-HLA antibodies. These are antibodies the recipient has already formed against the donor’s HLA molecules, sometimes from a previous transfusion, pregnancy, or transplant. Their presence can significantly increase the risk of primary graft failure, making pre-transplant antibody screening a standard part of the workup.15Bone Marrow Transplantation. HLA matching in contemporary haematopoietic cell transplantation: Recommendations from the EBMT Practice Harmonisation and Guidelines Committee
Autoimmune Disease and HLA
Certain HLA variants dramatically increase the risk of specific autoimmune diseases. The class II haplotype HLA-DRB1-DQA1-DQB1 has been linked to rheumatoid arthritis, type 1 diabetes, and Graves’ disease, among others.16PubMed Central. The HLA Region and Autoimmune Disease: Associations and Mechanisms of Action The connection makes biological sense: class II molecules are responsible for presenting external protein fragments to helper T cells, so a variant that happens to present a self-protein fragment particularly well could spark an immune attack against the body’s own tissues.
The suspected mechanism works at two stages. In the thymus, disease-predisposing HLA molecules may allow potentially self-reactive T cells to escape the deletion process that normally weeds them out, or they may fail to adequately select the regulatory T cells that keep the immune system in check. Outside the thymus, these same HLA variants may preferentially bind and display self-derived peptides that trigger autoimmune responses.17Transplant Immunology. HLA associated genetic predisposition to autoimmune diseases: Genes involved and possible mechanisms The result is a double vulnerability: faulty quality control during T cell development combined with an ongoing tendency to wave self-peptides in front of T cells that should never have been allowed to mature.
Drug Reactions Tied to HLA Type
One of the more actionable discoveries in HLA genetics is the link between specific HLA alleles and severe drug reactions. The best-known example involves abacavir, an HIV medication. Patients carrying the HLA-B*57:01 allele have a high risk of a dangerous hypersensitivity reaction to this drug, and pre-prescription genetic testing for this allele is now standard clinical practice in many countries. Other established links include HLA-B*15:02 and carbamazepine-induced Stevens-Johnson syndrome (a potentially fatal skin reaction), and HLA-B*38:02 and HLA-DRB1*08:03 with agranulocytosis caused by antithyroid drugs.18PubMed Central. HLA Association with Drug-Induced Adverse Reactions
These associations can vary by ancestry. The carbamazepine link illustrates this well: in Southeast Asian populations, HLA-B*15:02 is the primary risk allele for severe skin reactions, while in Northern European populations, a different allele, HLA-A*31:01, carries the risk. A genome-wide study found that HLA-A*31:01, present in roughly two to five percent of Northern Europeans, was associated with markedly elevated odds of carbamazepine hypersensitivity syndrome and Stevens-Johnson syndrome.19PubMed Central. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans This population-specific variation means that pharmacogenomic screening panels need to be tailored to the patient’s genetic background, not applied as a one-size-fits-all checklist.
Infectious Disease and the Advantage of Specific Alleles
HIV research has provided some of the clearest demonstrations that certain HLA types confer measurable advantages against specific pathogens. A small fraction of people infected with HIV-1 manage to suppress the virus to very low levels without antiretroviral therapy. These individuals, often called elite controllers or long-term non-progressors, are significantly enriched for protective HLA alleles like HLA-B*57, HLA-B*27, and HLA-B*58:01. One study of Spanish long-term non-progressors found that these individuals averaged about 1.4 protective HLA alleles and related genetic markers, compared to just 0.12 in HIV-negative controls from the same population, and the number of protective alleles correlated with better viral load control.20PubMed Central. Novel association of five HLA alleles with HIV-1 progression in Spanish long-term non progressor patients
The protection is not universal, though. HLA-B*57 and HLA-B*27, which are common protective alleles among Caucasians infected with HIV-1 clade B, do not show the same protection in sub-Saharan African populations infected with HIV-1 clade C.21PubMed Central. The influence of HLA/HIV genetics on the occurrence of elite controllers and a need for therapeutics geotargeting view The virus subtype matters because different clades present different peptide targets, and an HLA allele that efficiently presents clade B peptides to CD8+ T cells may not do the same for clade C peptides. This interaction between host genetics and pathogen genetics underscores why HLA diversity is maintained by natural selection: no single allele is universally “best,” and the advantage shifts with the pathogen landscape.
There is also a trade-off. Some of the same HLA alleles that protect against viral infections are associated with increased susceptibility to autoimmune conditions. HLA-B*27, for instance, is strongly linked to ankylosing spondylitis, and HLA-B*57 has been associated with psoriasis. These alleles appear to act as a double-edged sword: their aggressive peptide presentation helps control viruses but can also trigger inappropriate immune responses against self-tissues.22PubMed Central. Human Leukocyte Antigen (HLA) and Immune Regulation: How Do Classical and Non-Classical HLA Alleles Modulate Immune Response to Human Immunodeficiency Virus and Hepatitis C Virus Infections?
Non-Classical HLA Molecules and Pregnancy
Beyond the classical HLA genes that handle peptide presentation, the class I region also contains “non-classical” HLA genes with more specialized roles. HLA-G is the best-known example. Unlike classical class I molecules, which are found on nearly every cell, HLA-G has highly restricted expression. Its primary site of action is the placenta, specifically on the extravillous trophoblast cells that invade the uterine wall during early pregnancy. There, HLA-G interacts with receptors on maternal immune cells, including natural killer cells, T cells, and macrophages, to prevent the mother’s immune system from attacking the fetus.23PubMed Central. HLA-G: An Important Mediator of Maternal-Fetal Immune-Tolerance
The fetus is, immunologically speaking, half foreign: it carries paternal HLA molecules that the mother’s immune system has never seen. Uterine natural killer cells appear to be central to managing this situation. Rather than attacking the fetus, they regulate how deeply trophoblast cells penetrate and how uterine blood vessels remodel to supply the placenta. Genetic epidemiological data suggest that the particular combination of maternal NK cell receptors and fetal MHC molecules on trophoblast cells influences whether placentation proceeds normally or goes awry.24PubMed Central. Uterine NK cells: active regulators at the maternal-fetal interface Complications like pre-eclampsia and recurrent miscarriage have been linked to disruptions in this allorecognition process, though the details are still being worked out.
Cancer Immune Evasion
Because class I HLA molecules are the mechanism by which killer T cells identify abnormal cells, tumors that reduce or lose their HLA expression gain a survival advantage. Without class I molecules on the cell surface, even a highly activated immune system cannot “see” the tumor through its normal T cell surveillance pathway. Research suggests that between 60 and 90 percent of cancer patients may have some degree of HLA class I deregulation in their tumors even before any treatment begins, which would render many of them unable to respond fully to current immunotherapy approaches like checkpoint inhibitors.25PubMed Central. Deregulation of HLA-I in cancer and its central importance for immunotherapy
This is a significant problem for the field of cancer immunotherapy. Treatments like anti-PD-1 antibodies work by removing the brakes on T cells, but that strategy assumes the T cells can find their targets in the first place. If the tumor has already downregulated its class I molecules, unleashing more T cells does not help much. Researchers are exploring strategies to restore HLA expression on tumor cells, or to activate NK cells, which can actually target cells that lack class I molecules rather than cells that display them. The interplay between these two arms of the immune system, T cells needing HLA and NK cells responding to its absence, represents one of the more promising frontiers in cancer treatment design.
A Footnote from Forensics
Before DNA fingerprinting became routine, HLA typing was one of the most powerful tools available for paternity testing. In a study spanning six years and 866 disputed parentage cases, about 22 percent of alleged fathers were excluded as the biological parent. Of those exclusions, 92 percent were identified by HLA typing alone, with red blood cell antigen testing contributing the remaining 8 percent.26PubMed Central. Analysis of paternity. The use of HLA and red cell antigens The extreme polymorphism of HLA genes made them ideal for this purpose: because so many variants exist in the population, the chance of a false match between an unrelated man and a child was small. Modern forensics has moved on to short tandem repeat (STR) profiling, which is cheaper and even more discriminating, but HLA typing’s role in establishing the legal framework for genetic identity testing was foundational.